Lumosa Therapeutics, a public traded company in Taipei Exchange (6535.TWO), is dedicated to the development of innovative new drugs for the treatment of neurological and oncological diseases of unmet medical needs. The company is actively engaged in scientific in-licensing and new drug development under the “reSEARCH and DEVELOPMENT” model. This model is executed by a highly capable and experienced cross-functional teams of translational research, CMC, preclinical, clinical development, project management, regulatory affairs, intellectual property and business development experts. Current products/pipeline include Naldebain®, a long long-acting analgesic injection, launched in Taiwan in 2017, Singapore in 2020, and Thailand in 2021; LT3001, an NCE for the treatment of acute ischemic stroke currently under phase II clinical trial in the US and Taiwan; LT2003, tumor-targeting enzyme prodrug; and LT5001, a novel topical drug for uremic pruritus.
Location: Taiwan
Employees: 11-50
Founded date: 2001
Investors 1
| Date | Name | Website |
| - | YFY Biotec... | tgbfund.co... |
Mentions in press and media 2
| Date | Title | Description | Source |
| 02.02.2024 | Lumosa Therapeutics and CHI Memorial announce new study for ... | TAIPEI and CHATTANOOGA, Tenn., Feb. 2, 2024 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO), ... | en.prnasia... |
| 03.08.2021 | Lumosa Therapeutics Announces Positive Results from LT3001 P... | LT3001 met primary safety endpoint. No symptomatic intracranial hemorrhage occurred. LT3001 showed p... | en.prnasia... |